an experimental experience

http://www.clinicaltrialsarena.com/comment/aml-menin-inhibitors/

3/17/23 at 4:30pm

Organization

Author

33 words

Comments

The menin inhibitors revumenib and ziftomenib are in close competition for a share of the acute myeloid leukaemia (AML) market.

You are the first to view

Create an account or login to join the discussion